SCHEMBL1937452

SCHEMBL1937452

FC(F)(F)c1ccc(CNCC2CN(Cc3ccccc3)CC2c2cccc(Cl)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 4/20 0.53
ACHE P22303 3/20 0.47
BCHE P06276 2/20 0.47
BACE1 P56817 2/20 0.47
MCHR1 Q99705 1/20 0.45
KDM1A O60341 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
PAX8 Q06710 1/20 0.41
HTR2C P28335 1/20 0.41
HIF1A Q16665 1/20 0.40
EPAS1 Q99814 1/20 0.40
DPP4 P27487 1/20 0.40
S1PR1 P21453 1/20 0.39
GRK5 P34947 1/20 0.39
CDK8 P49336 1/20 0.39
S1PR5 Q9H228 1/20 0.39
CXCR4 P61073 1/20 0.39
SIGMAR1 Q99720 2/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1937260 0.88 ACHE (0.47) CCR5ACHEBCHEBACE1MCHR1
SCHEMBL1938346 0.79 KCNH2 (0.43) KDM1AMAOAMAOBPAX8HTR2C
SCHEMBL1937453 0.77 CCR5 (0.46) CCR5ACHEBCHEBACE1PAX8
SCHEMBL3031891 0.75 HIF1A (0.43) CCR5ACHEBCHEBACE1HIF1A
SCHEMBL1938171 0.75 CCR5 (0.67) CCR5HTR2CDPP4SIGMAR1
SCHEMBL4110124 0.73 S1PR5 (0.51) CCR5HTR2CS1PR1GRK5CDK8
SCHEMBL4102054 0.73 S1PR5 (0.51) CCR5HTR2CS1PR1GRK5CDK8
SCHEMBL20283105 0.73 CCR5 (0.53) CCR5DPP4SIGMAR1
SCHEMBL1937441 0.70 DPP4 (0.70) CCR5HTR2CDPP4S1PR1S1PR5
SCHEMBL29087682 0.70 S1PR5 (0.45) MCHR1PAX8HIF1AEPAS1S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364295-B1 3-(BENZYLAMINO)-PYRROLIDINE DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-02-27 EP disclosed
US-8293770-B2 Pyrrolidine derivatives as NK-3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-10-23 US disclosed
US-8022099-B2 N-benzyl pyrrolidine derivatives HOFFMANN-LA ROCHE INC. (US) 2011-09-20 US disclosed
EP-2364295-A1 3-(BENZYLAMINO)-PYRROLIDINE DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-09-14 EP disclosed
EP-2331500-A1 PYRROLIDINE N-BENZYL DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-06-15 EP disclosed
US-20100168088-A1 PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 US disclosed
WO-2010060703-A1 3-(BENZYLAMINO)-PYRROLIDINE DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-06-03 WO disclosed
US-20100113424-A1 N-BENZYL PYRROLIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 US disclosed
WO-2010040663-A1 PYRROLIDINE N-BENZYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168088-A1 PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS OPRK1, OPRL1, OPRD1 CCR5 934/4885ACHE 907/4885BCHE 3516/4885
US-20100113424-A1 N-BENZYL PYRROLIDINE DERIVATIVES OPRK1, OPRD1, OPRL1 CCR5 1534/4885ACHE 362/4885BCHE 1249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.